These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26656271)

  • 1. The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
    Mnguni AT; Engel ME; Borkum MS; Mayosi BM
    PLoS One; 2015; 10(12):e0143338. PubMed ID: 26656271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
    Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
    Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
    Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
    Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
    Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
    Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
    Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
    Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.
    Gao X; Xu H; Zhang B; Tao T; Liu Y; Xu D; Cai W; Wei Z; Li S; Zhang H; Mao N; Zhang G; Li D; Jin F; Li S; Zhang L; Liu H; Hao X; Yang F
    Exp Physiol; 2019 Oct; 104(10):1562-1574. PubMed ID: 31290182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells.
    Kanasaki K; Koya D; Sugimoto T; Isono M; Kashiwagi A; Haneda M
    J Am Soc Nephrol; 2003 Apr; 14(4):863-72. PubMed ID: 12660320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
    Castoldi G; di Gioia CR; Bombardi C; Perego C; Perego L; Mancini M; Leopizzi M; Corradi B; Perlini S; Zerbini G; Stella A
    Clin Sci (Lond); 2009 Oct; 118(3):211-20. PubMed ID: 20310083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
    Peng H; Carretero OA; Raij L; Yang F; Kapke A; Rhaleb NE
    Hypertension; 2001 Feb; 37(2 Pt 2):794-800. PubMed ID: 11230375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.
    Hrenak J; Paulis L; Simko F
    Curr Pharm Des; 2015; 21(35):5135-43. PubMed ID: 26350537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.
    Cavasin MA; Rhaleb NE; Yang XP; Carretero OA
    Hypertension; 2004 May; 43(5):1140-5. PubMed ID: 15037553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the antifibrotic potential of N-acetyl seryl-aspartyl-lysyl-proline sequence peptides.
    Ramasamy V; Ntsekhe M; Sturrock E
    Clin Exp Pharmacol Physiol; 2021 Nov; 48(11):1558-1565. PubMed ID: 34347311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry.
    Inoue K; Ikemura A; Tsuruta Y; Watanabe K; Tsutsumiuchi K; Hino T; Oka H
    J Pharm Biomed Anal; 2011 Mar; 54(4):765-71. PubMed ID: 21074346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.
    Kumar N; Yin C
    Pharmacol Res; 2018 Aug; 134():268-279. PubMed ID: 29990624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.
    Zhang X; Zhou J; Zhu Y; He L; Pang Z; Wang Z; Xu C; Zhang C; Hao Q; Li W; Zhang W; Zhang Y; Li M
    IUBMB Life; 2019 Sep; 71(9):1302-1312. PubMed ID: 30900390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
    Rasoul S; Carretero OA; Peng H; Cavasin MA; Zhuo J; Sanchez-Mendoza A; Brigstock DR; Rhaleb NE
    J Hypertens; 2004 Mar; 22(3):593-603. PubMed ID: 15076166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
    Azizi M; Rousseau A; Ezan E; Guyene TT; Michelet S; Grognet JM; Lenfant M; Corvol P; Ménard J
    J Clin Invest; 1996 Feb; 97(3):839-44. PubMed ID: 8609242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
    Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
    J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.
    Romero CA; Kumar N; Nakagawa P; Worou ME; Liao TD; Peterson EL; Carretero OA
    Am J Physiol Renal Physiol; 2019 Jan; 316(1):F195-F203. PubMed ID: 30403163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension.
    Peng H; Carretero OA; Brigstock DR; Oja-Tebbe N; Rhaleb NE
    Hypertension; 2003 Dec; 42(6):1164-70. PubMed ID: 14581293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.